Detalhe da pesquisa
1.
Prevention efficacy of the broadly neutralizing antibody VRC01 depends on HIV-1 envelope sequence features.
Proc Natl Acad Sci U S A
; 121(4): e2308942121, 2024 Jan 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38241441
2.
Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition.
N Engl J Med
; 384(11): 1003-1014, 2021 03 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-33730454
3.
Protein dose-sparing effect of AS01B adjuvant in a randomized preventive HIV vaccine trial of ALVAC-HIV (vCP2438) and adjuvanted bivalent subtype C gp120.
J Infect Dis
; 2023 Oct 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37795976
4.
Selection of HIV Envelope Strains for Standardized Assessments of Vaccine-Elicited Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies.
J Virol
; 96(2): e0164321, 2022 01 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-34730393
5.
Optimizing clinical dosing of combination broadly neutralizing antibodies for HIV prevention.
PLoS Comput Biol
; 18(4): e1010003, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35385469
6.
Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein.
Clin Infect Dis
; 72(1): 50-60, 2021 01 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-31900486
7.
Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials.
PLoS Med
; 17(5): e1003117, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32442195
8.
HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees.
J Virol
; 92(8)2018 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29386288
9.
Histo-Blood Group Antigen Phenotype Determines Susceptibility to Genotype-Specific Rotavirus Infections and Impacts Measures of Rotavirus Vaccine Efficacy.
J Infect Dis
; 217(9): 1399-1407, 2018 04 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-29390150
10.
Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial.
J Infect Dis
; 217(8): 1280-1288, 2018 03 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-29325070
11.
SieveSifter: a web-based tool for visualizing the sieve analyses of HIV-1 vaccine efficacy trials.
Bioinformatics
; 33(15): 2386-2388, 2017 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28379332
12.
Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2.
Nature
; 490(7420): 417-20, 2012 Oct 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-22960785
13.
Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial.
J Infect Dis
; 215(8): 1255-1263, 2017 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28329190
14.
Comprehensive sieve analysis of breakthrough HIV-1 sequences in the RV144 vaccine efficacy trial.
PLoS Comput Biol
; 11(2): e1003973, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25646817
15.
Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial.
J Virol
; 88(15): 8242-55, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24829343
16.
Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence features.
Nat Commun
; 15(1): 2175, 2024 Mar 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38467646
17.
Human immunoglobulin gene allelic variation impacts germline-targeting vaccine priming.
NPJ Vaccines
; 9(1): 58, 2024 Mar 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38467663
18.
Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections.
PLoS Pathog
; 7(9): e1002209, 2011 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-21980282
19.
A first-in-human germline-targeting HIV nanoparticle vaccine induced broad and publicly targeted helper T cell responses.
Sci Transl Med
; 15(697): eadf3309, 2023 05 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-37224227
20.
High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials.
Nat Commun
; 14(1): 8299, 2023 Dec 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38097552